Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on January 6, 2023, covering events that occurred on January 5, 2023. The filing primarily addresses significant changes to the composition and leadership of the Company's Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Fee: $55,000 for the newly elected non-employee director.
- Initial Stock Option Grant: 4,268 shares with an aggregate grant date fair value of $600,000.
- Option Exercise Price: $225.68 per share.
- Future Annual Option Grant Value: Approximately $400,000 (subject to Board determination).
Material Changes
The following material changes to corporate governance were effective as of January 5, 2023:
- Board Expansion: The Board size increased from eleven to twelve members.
- New Director Election: Dr. Carolyn R. Bertozzi was elected as a Class III director, with a term expiring in 2025.
- Leadership Transition: Michael W. Bonney transitioned from Executive Chair to a standard director role.
- Chair Appointment: Amy W. Schulman, previously the Lead Independent Director, was appointed as the new Chair of the Board.
Guidance, Outlook, and Risks
This filing contains no financial guidance, operational outlook, or discussion of business risks and contingencies. The document focuses exclusively on the appointment of a new director and the restructuring of the Board's chairmanship.
Key Facts for Investor Verification
- Verify the impact of the leadership transition from Michael W. Bonney to Amy W. Schulman on the Company's strategic direction.
- Confirm the vesting schedule for Dr. Bertozzi's initial stock options (ratably over three years starting one year post-grant).
- Review the full press release (Exhibit 99.1) for additional context on the Board's rationale for these changes.
- Note that this filing does not contain updated financial results; refer to the most recent 10-Q or 10-K for financial status.